Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468570 · ClinicalTrials.gov registry record
A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302
A clinical trial, sponsored by BioMarin Pharmaceutical.
- Completed
- Registry status
- 9
- Enrollment target
NCT02468570: Completed study, sponsored by BioMarin Pharmaceutical.
NCT02468570 is a clinical trial that has completed, run by BioMarin Pharmaceutical. The registered enrollment target is 9 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02468570 has completed, sponsored by BioMarin Pharmaceutical.
- COMPLETED
- Registry status
- 9 participants
- Enrollment target
Study Summary
A Phase 3 substudy to evaluate executive function in adults with phenylketonuria who are participating in the phase 3 Study, 165-302. Approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU will be enrolled.
Primary Outcome
The RVP task measures sustained attention. In this task, a series of random digits continuously appears in the middle of the screen. Subjects are asked to recognize a specific sequence of digits and are asked to press a button on the screen whenever this specific sequence of digits appears within this series of continuous digits. RVP mean latency is the mean response latency during assessment sequence blocks where the subject responded correctly (Latency units are milliseconds). Lower scores re
Interventions
- OTHER Administration of CANTAB and Subject Global Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-08-05 |
| Est. Completion | 2017-02-01 |
What the finished NCT02468570 record still lists
NCT02468570 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 9 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Administration of CANTAB and Subject Global Assessment is the first listed.
NCT02468570 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02468570 about?
NCT02468570 is a clinical study titled "A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302". A Phase 3 substudy to evaluate executive function in adults with phenylketonuria who are participating in the phase 3 Study, 165-302. Approximately 100 subjects, aged ≥ 18 to ≤ 70 years old, with PKU will be enrolled.
What is the current status of trial NCT02468570?
This trial is currently completed. The enrollment target is 9 participants. The study started on 2015-08-05. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02468570?
The interventions under investigation include: Administration of CANTAB and Subject Global Assessment (OTHER).
Who is sponsoring clinical trial NCT02468570?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI